Skip to content
Loading...
SynAct Pharma logo
  • About
    • Management
    • Board of Directors
    • Advisory Board
    • History
    • Governance
      • General Meetings
      • Governance reports
      • Board Committees
      • Nomination Committee
      • Articles of Association
      • Auditor
    • Code of Conduct
    • Career
  • Our Science
    • Focus Areas
      • Autoimmune and Inflammatory Diseases
      • Host-Directed Therapy – Viral Infections
    • Our Medicines
      • Oral Drugs
      • Peptides
    • Synact Wiki
  • Diseases
    • Rheumatoid Arthritis
    • Nephrotic Syndrome
    • Polymyalgia Rheumatica
    • Dengue Fever
    • COVID-19
  • Development Program
    • Resomelagon
      • Inflammatory and Autoimmune Diseases
        • RA: The BEGIN Study
        • RA: The EXPAND Study
        • RA: The RESOLVE Study
        • RA: The ADVANCE Study
        • iMN: SynAct-CS003
      • Host-Directed Therapy in Viral Infections
        • COVID-19: RESOVIR-1
        • Dengue Fever: RESOVIR-2
    • TXP-11
  • Investors
    • Message from the CEO
    • Investment Highlights
    • Financial Reports
    • The Share
      • Share capital
    • Ownership Structure
    • Board and Management Holdings
    • Analysts
    • Presentations
    • Calendar
    • Prospectus and Rights Issues
  • News & Media
    • News and Press Releases
    • SynAct in the Media
    • Slide Decks and Presentations
    • Image Bank
  • ENG
  • SVE

Annual General Meeting 2023

May 25, 2023

The Annual general meeting in SynAct Pharma AB, Reg. No. 559058-4826 (“SynAct”) was held on Thursday May 25, 2023.

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Documents

  • Minutes from the AGM 2023 May 25, 2023 - English
  • Notice of annual general meeting 2023 April 13, 2023 - English
  • Power of Attorney English
  • Proposal on authorization regarding issues English
  • Proposal on resolution on amendment of the Articles of Association English
  • Proposal for resolution on (A) employee option program; and (B) directed issue of warrants English
  • Remuneration report 2022 English
  • The Nomination Committee's proposals and reasoned statement English
  • Auditor’s opinion under Chapter 8 Section 54 of the Swedish Companies Act English
  • Press release - Bulletin from the annual general meeting in SynAct Pharma AB on May 25, 2023 May 25, 2023 - English
About
  • Management
  • Board of Directors
  • Advisory Board
  • History
  • Governance
    • General Meetings
    • Governance reports
    • Board Committees
    • Nomination Committee
    • Articles of Association
    • Auditor
  • Code of Conduct
  • Career

SynactPharma-white

Advancing medicine trough
melanocortin activation

SynAct Pharma AB (publ)
Scheelevägen 2
SE-223 63 Lund
Sweden

Synact Pharma ApS
Dronninggårds Alle 136
2840 Holte
Denmark

  • About
  • Our Science
  • Diseases
  • Development Program
  • Investors
  • News & Media
  • Privacy Policy
  • Cookies
  • Get the latest news follow us on Linkedin

© 2025 SynAct Pharma AB. All right reserved.